Cognitive changes in asymptomatic carriers of the Huntington disease mutation gene
- PMID: 17941857
- DOI: 10.1111/j.1468-1331.2007.01975.x
Cognitive changes in asymptomatic carriers of the Huntington disease mutation gene
Abstract
Huntington disease (HD) is a neurodegenerative disorder due to an excessive number of CAG repeats in the IT15 gene on chromosome 4. Studies of cognitive function in asymptomatic gene carriers have yielded contradictory results. This study compared cognitive performance in 44 subjects with the HD mutation (group of carriers) who had no clinical signs of HD and 39 at-risk individuals without HD mutation (group of non-carriers). Neuropsychological evaluation focused on global cognitive efficiency, psychomotor speed, attentional, executive and memory functions. Significant differences, with lower performances in the group of gene carriers, were detected for some measures of psychomotor speed, attention and executive functioning (all P < 0.01). More differences between groups were observed for memory measures, in particular on the California Verbal Memory Test. Complementing these observations, cognitive scores were correlated with age in the group of gene carriers, but not in the group of non-carriers. This suggests that the cognitive changes precede the appearance of the motor and psychiatric symptoms in HD and that tests proved to be sensitive to early HD deficiencies are better suited than global cognitive efficiency scales to observe them.
Similar articles
-
Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers.J Neurol Neurosurg Psychiatry. 1998 Feb;64(2):172-7. doi: 10.1136/jnnp.64.2.172. J Neurol Neurosurg Psychiatry. 1998. PMID: 9489526 Free PMC article. Clinical Trial.
-
Cognition in Huntington's disease in manifest, premanifest and converting gene carriers over ten years.J Huntingtons Dis. 2013;2(2):137-47. doi: 10.3233/JHD-130059. J Huntingtons Dis. 2013. PMID: 25063511
-
Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation--a longitudinal follow-up study.J Neurol. 2004 Aug;251(8):935-42. doi: 10.1007/s00415-004-0461-9. J Neurol. 2004. PMID: 15316797
-
[From gene to disease; HD gene and Huntington disease].Ned Tijdschr Geneeskd. 2001 Nov 3;145(44):2120-3. Ned Tijdschr Geneeskd. 2001. PMID: 11723754 Review. Dutch.
-
Huntington disease: clinical, genetic, and social aspects.J Geriatr Psychiatry Neurol. 1998 Summer;11(2):61-70. doi: 10.1177/089198879801100204. J Geriatr Psychiatry Neurol. 1998. PMID: 9877527 Review.
Cited by
-
Organoselenium bis selenide attenuates 3-nitropropionic acid-induced neurotoxicity in rats.Neurotox Res. 2013 Apr;23(3):214-24. doi: 10.1007/s12640-012-9336-5. Epub 2012 Jun 28. Neurotox Res. 2013. PMID: 22739838
-
Dendritic spine instability leads to progressive neocortical spine loss in a mouse model of Huntington's disease.J Neurosci. 2013 Aug 7;33(32):12997-3009. doi: 10.1523/JNEUROSCI.5284-12.2013. J Neurosci. 2013. PMID: 23926255 Free PMC article.
-
Characterization of visual cognition in pre-manifest, manifest and reduced penetrance Huntington's disease.Sci Rep. 2025 Feb 8;15(1):4707. doi: 10.1038/s41598-025-88406-5. Sci Rep. 2025. PMID: 39922862 Free PMC article.
-
Use of the frontal assessment battery in evaluating executive dysfunction in patients with Huntington's disease.J Neurol. 2009 Nov;256(11):1809-15. doi: 10.1007/s00415-009-5197-0. Epub 2009 Jun 18. J Neurol. 2009. PMID: 19536583
-
Huntington's disease: the coming of age.J Genet. 2018 Jul;97(3):649-664. J Genet. 2018. PMID: 30027901 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical